The Role for Interleukin-12 Therapy of Cutaneous T Cell Lymphoma

• Published in: Annals of the New York Academy of Sciences Vol. 941; no. 1; pp. 177 - 184
• Main Authors: ROOK, ALAIN H., ZAKI, MOHAMED H., WYSOCKA, MARIA, WOOD, GARY S., DUVIC, MADELEINE, SHOWE, LOUISE C., FOSS, FRANCINE, SHAPIRO, MICHAEL, KUZEL, TIMOTHY M., OLSEN, ELISE A., VONDERHEID, ERIC C., LALIBERTE, ROBERT, SHERMAN, MATTHEW L.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.09.2001
• Subjects: Antigens, Differentiation, T-Lymphocyte - analysis; Antigens, Differentiation, T-Lymphocyte - immunology; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Humans; Immunohistochemistry; interferon-γ; Interleukin-12 - adverse effects; Interleukin-12 - therapeutic use; interleukin-2; Lymphocytes, Tumor-Infiltrating - immunology; Lymphoma, T-Cell, Cutaneous - drug therapy; Lymphoma, T-Cell, Cutaneous - immunology; recombinant human interleukin-12; Recombinant Proteins - therapeutic use; Skin Neoplasms - drug therapy; Skin Neoplasms - immunology; T-Lymphocyte Subsets - classification; T-Lymphocytes, Cytotoxic - immunology; Treatment Outcome
• ISSN: 0077-8923; 1749-6632
• DOI: 10.1111/j.1749-6632.2001.tb03721.x

: Recent phase I and phase II trials using recombinant human interleukin‐12 (rhIL‐12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA‐1+ T cells. These results suggest that rhIL‐12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL‐12.